WILLIAM J. CHASE - 20 Aug 2025 Form 4 Insider Report for Intellia Therapeutics, Inc. (NTLA)

Role
Director
Signature
/s/ James Basta, attorney-in-fact
Issuer symbol
NTLA
Transactions as of
20 Aug 2025
Net transactions value
+$1,003,000
Form type
4
Filing time
22 Aug 2025, 16:30:14 UTC
Previous filing
17 Jul 2025
Next filing
16 Oct 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
CHASE WILLIAM J Director C/O INTELLIA THERAPEUTICS, INC., 40 ERIE STREET, SUITE 130, CAMBRIDGE /s/ James Basta, attorney-in-fact 22 Aug 2025 0001563572

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NTLA Common Stock Purchase $1,003,000 +100,000 +288% $10.03 134,693 20 Aug 2025 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects an open market purchase of shares of the Issuer's common stock by the Reporting Person in accordance with the Issuer's trading policies.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $9.97 to $10.04, inclusive. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares purchased by the reporting person on August 20, 2025 at each separate price.